[PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects]

Area of Science:

• Biochemistry
• Molecular Biology
• Genetics

Background:

• Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low-density lipoprotein receptor (LDLr), inhibiting LDLr recycling to the hepatocyte surface.
• This interaction leads to lysosomal degradation of LDLr, reducing the clearance of LDL-cholesterol (LDLc) from the blood.
• Gain-of-function mutations in PCSK9 elevate LDLc, while loss-of-function mutations lower LDLc and reduce coronary heart disease risk.

Purpose of the Study:

• To review recent findings on PCSK9 gene regulation.
• To explore the molecular mechanisms of PCSK9 in cholesterol homeostasis.
• To highlight PCSK9 as a therapeutic target for managing blood cholesterol levels.

Main Methods:

• Literature review of recent scientific data.
• Analysis of molecular function and regulatory pathways of PCSK9.
• Discussion of genetic variations and their impact on cholesterol levels.

Main Results:

• PCSK9 plays a critical role in LDLr metabolism and cholesterol homeostasis.
• Dysregulation of PCSK9 is linked to hypercholesterolemia and cardiovascular disease.
• Recent research provides insights into PCSK9's complex regulatory network.

Conclusions:

• PCSK9 is a significant factor in maintaining cholesterol balance.
• Targeting PCSK9 offers a promising strategy for reducing LDLc.
• Further research into PCSK9 regulation and function can lead to novel therapeutic interventions.